Protocol 2001133:..Study to Evaluate Efficacy and Safety of Transdermal Testosterone (300 ug/day) for 24 Weeks and Safety for a Further 28-Week Open-Label Period in Women with Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy